Conversion of tacrolimus-treated maintenance renal transplant patients from MMF to EC-MPS is safe and well-tolerated and does not compromise therapeutic ...

This study demonstrates that there is no good evidence supporting the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium for the ...

The 3-month interim analyses suggest that the conversion from MMF to EC-MPS is well tolerated in maintenance renal transplant recipients.

An elective conversion of CellCept to Myfortic was performed in 15 heart transplant recipients (13 men and 2 women, 45.9 ± 8.5 years of age, 38 ± 32 months ...

The 3 months interim analysis suggests that renal transplant patients receiving MMF can be converted to EC-MPS with no efficacy or tolerability compromise.

Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels. Nephrol Dial ...

21 июл. 2015 г. · Patients switched to EC-MPS experienced less gastrointestinal symptom burden and showed improvement in HRQoL.

Mycophenolate mofetil, a prodrug, is rapidly converted after oral administration into the active drug mycophenolic acid by esterases present in the gut wall, ...

... mycophenolic acid (MPA). The aim of this prospective study was to evaluate the effect of conversion from mycophenolate mofetil (MMF) to enteric-coated.

22 окт. 2024 г. · Mycophenolate is also widely used as a glucocorticoid-sparing agent for the treatment of patients with a variety of rheumatic diseases.